Cogent Biosciences, Inc. (COGT) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en Waltham, MA, United States. El CEO actual es Andrew R. Robbins.
COGT tiene fecha de IPO 2018-03-29, 205 empleados a tiempo completo, cotiza en el NASDAQ Global Select, una capitalización de mercado de $5.92B.
Cogent Biosciences, Inc. is a biotechnology company focused on developing precision therapies for genetically defined diseases. The company's lead product candidate, CGT9486, is a selective tyrosine kinase inhibitor designed to treat systemic mastocytosis and advanced gastrointestinal stromal tumors by targeting specific KIT mutations. Cogent also holds a licensing agreement with Plexxikon Inc. for the development and commercialization of bezuclastinib. Headquartered in Cambridge, Massachusetts, the company was founded in 2014 and rebranded from Unum Therapeutics Inc. to Cogent Biosciences, Inc. in October 2020.
